Loading
Life sciences · Journal article
Current Issues in Molecular Biology · October 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cannabinoids have gained increasing attention as potential anticancer agents because of their ability to modulate diverse cancer-associated signaling pathways and biological processes.: Cannabinoids, including cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), can influence tumor proliferation, apoptosis, angiogenesis, metabolism, immune regulation, and tumor–microenvironment interactions. However, clinical translation remains limited, as evidence of anticancer efficacy is derived predominantly from preclinical studies. Major knowledge gaps include the absence of validated predictive biomarkers, unclear criteria for patient selection, and limited evidence regarding optimal therapeutic and combination strategies. Thus, the central challenge is to identify the patients and tumor contexts most likely to benefit from cannabinoid-based therapy. We propose a precision cannabinoid oncology framework that integrates molecular characterization, molecular classification, predictive biomarker development, rational combination strategies, and prospective clinical validation. This approach may provide a conceptual foundation for moving cannabinoid oncology from broadly empirical investigation toward molecularly informed patient selection and prospective validation of cannabinoid-based therapies in molecularly defined patient populations.